Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma.
The recombinant CD3 immunotoxin, A-dmDT(390)-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3epsilon monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.
Frankel
A E
AE
Scott & White Cancer Research Institute, 5701 S. Airport Road, Temple, TX 76502, USA. afrankel@swmail.sw.org
Zuckero
S L
SL
Mankin
A A
AA
Grable
M
M
Mitchell
K
K
Lee
Y J
YJ
Neville
D M
DM
Woo
J H
JH
D000368:Aged; D017252:CD3 Complex / Q000276:immunology; D004167:Diphtheria Toxin / Q000009:adverse effects / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000628:therapy*
D017252:CD3 Complex; D004167:Diphtheria Toxin; D000922:Immunotoxins; D011993:Recombinant Fusion Proteins